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Introduction {#cam41230-sec-0001}
============

Gastric cancer (GC) is the second leading cause of cancer‐related death worldwide, with China having the largest pool of advanced GC cases [1](#cam41230-bib-0001){ref-type="ref"}, for which high‐level surgical and medical prowess are required to improve survival. Patients often travel long distances to specialized cancer centers mainly for surgeries but often prefer their local hospitals for adjuvant therapies. As such, to enable a standardized treatment, staging of the disease is therefore the fundamental common language between surgical and medical oncologists.

The most recognized evidence‐based GC staging system in practice is the tumor‐node‐metastasis (TNM) concept from the American Joint Committee on Cancer (AJCC). Since the release of its first edition in 1977 [2](#cam41230-bib-0002){ref-type="ref"}, it has been updated every few years based on new breakthroughs in oncology.

Starting from the fifth AJCC GC edition, the anatomic nodal classification was discontinued and reporting the number of surgically retrieved lymph nodes (LNs) became the proposed standard [3](#cam41230-bib-0003){ref-type="ref"}. The sixth edition had only minor updates that did not influence the main staging of the disease [4](#cam41230-bib-0004){ref-type="ref"}. As such, in this study they were considered alike and labeled as the fifth/sixth edition. However, the seventh edition brought considerable modifications to the pathological classification of the depth of tumor invasion (pT) and completely redefined the classification of metastasized lymph nodes (pN) [5](#cam41230-bib-0005){ref-type="ref"}.

The eighth edition was recently released and includes the implementation of a clinical stage group, a postneoadjuvant stage group and several substantial revisions to the pathological stage group (pTNM) [6](#cam41230-bib-0006){ref-type="ref"}. The major changes hallmarked in this new edition are firstly, separating the pN3ab regional lymph nodes from the seventh edition into pN3a and pN3b in its main stage groupings. Secondly, the anatomic boundary demarcating esophageal and gastric cancer for tumors arising at the esophagogastric junction (EGJ) was adjusted from 5 cm to 2 cm.

Previous publications comparing the prognostic and discriminative abilities between the seventh and the sixth gastric cancer editions lacked detailed‐enough analyses, which might have contributed to the conflicting results published [7](#cam41230-bib-0007){ref-type="ref"}, [8](#cam41230-bib-0008){ref-type="ref"}, [9](#cam41230-bib-0009){ref-type="ref"}, [10](#cam41230-bib-0010){ref-type="ref"}, [11](#cam41230-bib-0011){ref-type="ref"}. In addition, since the implemented updates mainly affect patients with higher‐staged disease and Chinese patients are comparatively diagnosed at a more advanced stage, our primary aim was to use our Chinese cohort to perform a comprehensive analysis comparing the discriminative and prognostic ability of the eighth AJCC GC pathological classification to that of the seventh and fifth/sixth editions and secondly, to assess their long‐term significance.

Methods {#cam41230-sec-0002}
=======

Patient cohort {#cam41230-sec-0003}
--------------

From the prospectively recorded database of the Gastric Surgical Division of Sun Yat‐sen University Cancer Center, Guangzhou, China, a total of 2151 GC patients who had undergone surgical resection from January 1990 to December 2013 were identified. The patients' data were screened according to the following inclusion criteria: (1) thorough preoperative examinations including histologically confirmed adenocarcinoma of the stomach with no previous cancer history; (2) radical gastrectomy with radiological/pathological examination confirming the absence of synchronous or metachronous malignancies; (3) no neoadjuvant therapies; and (4) complete clinicopathological data to enable restaging according to the different AJCC TNM classifications.

The patients were followed every 3 months in the first 2 years after surgery, every 6 months for the next 3 years and then annually afterwards. Clinical examinations including general complete physical, hematological, and radiological tests were performed as required. The last day of follow‐up was February 2017.

Surgical treatment and pathological classification {#cam41230-sec-0004}
--------------------------------------------------

Patients with endoscopic or radiologic confirmation of gastric cancer involving the esophagus are often treated at the Thoracic Department of our Cancer Center. For consistency in surgical treatment, they were not included in this study. Expert gastric surgeons, each with an individual experience of at least 2000 gastrectomies, performed the surgical procedures according to the Japanese Gastric Cancer Association guidelines.

In this study, early, middle, and locally advanced disease referred to stages IA, IB to IIIA and IIIB to IIIC according to the eighth AJCC GC staging system, respectively and, combined resection referred to dissection of the spleen, pancreas and/or liver in addition to gastrectomies for achieving R0 resection.

All specimens were processed postoperatively by one of the operating surgeons before being submitted to expert pathologists whereby they were staged according to the most recent AJCC TNM classification at that time. For this study, each case was restaged according to the fifth/sixth, seventh and eighth AJCC GC pathological staging system. This retrospective study received the approval of the Institutional Review Board of the Ethical Committee of Sun Yat‐sen University Cancer Center, and upon final analysis, 1797 patients were observed to match the inclusion criteria.

Statistical analysis {#cam41230-sec-0005}
--------------------

Survival time was calculated from the date of surgery till the last day of follow‐up or tumor‐related death. Kaplan--Meier was used to calculate survival time and for statistical comparison of prognosis. The Cox proportional hazard model with forward stepwise regression was used to compute three separate multivariate analyses, namely, Multivariate 1, 2 and 3, which consisted of the parameters found to be significant in the univariate analysis for the fifth/sixth, seventh and eighth editions, respectively.

To identify the model with the best predictive ability, their corresponding Akaike information criterion (AIC) and Bayesian information criterion (BIC) with 95% CIs from bootstrapping of the original data [12](#cam41230-bib-0012){ref-type="ref"} were also computed.

Next, to assess whether their prognostic abilities would change over the years, we performed time‐dependent receiver operating characteristic (ROC) analyses of the area‐under‐curve (AUC), based on the predictive value of multivariate analyses, with 95% CI for the first, second, third, fourth, fifth, and tenth postoperative years. Their discriminative abilities were assessed by analyzing and comparing the range and gap of their survival curves.

Statistical analyses were performed using SPSS software (version 22.0, SPSS Inc., Chicago, IL) and R statistical software (version 3.3.1, the *R* Foundation for Statistical Computing). A *P*‐value less than 0.05 (2‐sided) was considered to be statistically significant.

Results {#cam41230-sec-0006}
=======

Patient characteristics {#cam41230-sec-0007}
-----------------------

Patients with stage III disease, according to the eighth edition, amounted to 51% (*n* = 916) of the cases. The mean age of the study population was 56.8 years (range, 16--90 years), and the 5‐year overall survival rate was 65.8 ± 2.876% (rate ± SD). In this study, there was a total of 37,682 LNs examined for which an average number of 21 LNs were recorded per patient. With regard to the 131 patients who had combined resection, a small percentage of them (*n* = 13; 9.9%) experienced postoperative complications, among which 109 (83.2%) had tumors greater than 4.5 cm (ranging from 5 cm to 18 cm), 89.3% being locally advanced and with the majority of them (35.1%) located in the upper third of the stomach. The median follow‐up time was 45 months (range, 1--259 months).

Change in patient distribution {#cam41230-sec-0008}
------------------------------

No change in distribution was observed in stage IA of the three editions. Patients in stage IB (*n* = 203) of the fifth/sixth edition were reclassified to stage IB (*n* = 107) and IIA (*n* = 96) in the eighth edition, those in stage II (*n* = 461) were reclassified to stage IIA (*n* = 34), IIB (*n* = 368) and IIIA (*n* = 59), and those in stage IIIA (*n* = 502) were reclassified to stage IIIA (*n* = 441) and IIIB (*n* = 61) in the new edition. Finally, patients in stage IIIB (*n* = 157) of the fifth/sixth edition were reclassified to stage IIIB (*n* = 154) and IIIC (*n* = 3), and those in stage IV (*n* = 198) were reclassified to stage IIIB (*n* = 34) and IIIC (*n* = 164), respectively. A large proportion of the patients (*n* = 1346; 74.9%) were upstaged in the new GC edition, and no down‐staging between these two classifications was observed.

From the seventh to the eighth edition, no change in distribution was found for 76% of the patients. A small percentage (*n* = 5; 1.4%) of patients from stage IIB in the seventh edition was reclassified to stage IIIB in the new edition. Those in stage IIIB (*n* = 332) were reclassified to stage IIIA (*n* = 232), IIIB (*n* = 75) and IIIC (*n* = 25), while those in stage IIIC (*n* = 311) were reclassified to stage IIIB (*n* = 169) and IIIC (*n* = 142), respectively. In all, 1.7% and 22.3% of patients from the seventh edition were up‐staged and down‐staged in the eighth edition, respectively.

Survival analysis {#cam41230-sec-0009}
-----------------

Of the eighteen clinicopathological factors analyzed in univariate analysis, only sex showed no correlation with survival (Table [1](#cam41230-tbl-0001){ref-type="table-wrap"}). A continuous decrease in 5‐year overall survival (OS) rate with an increase in increment of the pTNM classification as well as a gradual increase in their HR values and larger range of 95% confidence intervals (Table [1](#cam41230-tbl-0001){ref-type="table-wrap"} and Fig. [1](#cam41230-fig-0001){ref-type="fig"}A--C; *P *\<* *0.001) demonstrated the progressive improvement in demarcation of prognoses between the stages from the fifth/sixth to the eighth edition.

###### 

Correlation of patients demographics and clinical characteristics with survival

  -------------------------------------------------------------------------------------------------------------------
  Characteristics                     No. of cases   Cases (%)   5‐year OS (%)   HR       95% CI          *P*‐value
  ----------------------------------- -------------- ----------- --------------- -------- --------------- -----------
  Sex                                                                                                     0.554

  Male                                1207           67.2        62.6            Ref                      

  Female                              590            32.8        60.9            1.049    0.895--1.230    

  Age (years)                                                                                             \<0.001

  ≤64                                 1318           73.3        65.1            Ref                      

  \>64                                479            26.7        53.9            1.574    1.346‐1.841     

  Tumor location                                                                                          \<0.001

  \>1/3 of stomach                    161            9.0         39.6            Ref                      

  Upper 1/3                           570            32.0        51.1            0.730    0.576--0.923    

  Middle 1/3                          155            8.6         71.8            0.376    0.265--0.534    

  Lower 1/3                           911            50.7        71.1            0.352    0.277--0.447    

  Tumor size (cm)                                                                                         \<0.001

  \<4.5                               806            44.9        74.8            Ref                      

  4.5 ≤ *T *\<* *8.0                  617            34.3        58.1            1.816    1.515--2.1977   

  ≥8.0                                374            20.8        41.3            2.980    2.468--3.598    

  Bormann type                                                                                            \<0.001

  I                                   143            8.0         84.2            Ref                      

  II                                  586            32.6        71.1            2.108    1.356--3.277    

  III                                 986            54.9        55.4            3.480    2.267--5.342    

  IV                                  82             4.5         35.5            6.096    3.684--10.089   

  Differentiation                                                                                         0.039

  High/moderate                       360            20.0        65.8            Ref                      

  Poor/undifferentiated/signet cell   1437           80.0        61.1            1.227    1.010--1.491    

  Type of gastrectomy                                                                                     \<0.001

  Proximal                            496            27.6        50.3            Ref                      

  Distal                              987            54.9        71.3            0.467    0.395--0.552    

  Total                               314            17.5        50.0            0.971    0.792--1.190    

  Combined resection                                                                                      \<0.001

  No                                  1666           92.7        64.2            Ref                      

  Yes                                 131            7.3         35.9            2.338    1.865--2.931    

  Postoperative complication                                                                              0.029

  No                                  1724           95.9        62.7            Ref                      

  Yes                                 73             4.1         46.6            1.464    1.037--2.067    

  Retrieved lymph nodes                                                                                   \<0.001

  \<16                                749            41.7        55.7            Ref                      

  ≥16                                 1048           58.3        66.7            0.649    0.558--0.754    

  Adjuvant chemotherapy                                                                                   \<0.001

  No                                  1321           73.5        64.3            Ref                      

  Yes                                 476            26.5        55.8            1.335    1.139--1.564    

  Fifth/Sixth edition\                                                                                    \<0.001
  pT                                                                                                      

  T1                                  399            22.2        86.9            Ref                      

  T2                                  383            21.3        71.0            2.794    1.996--3.910    

  T3                                  904            50.3        51.0            5.184    3.850--6.981    

  T4                                  111            6.2         35.6            8.494    5.910--12.206   

  Fifth/Sixth edition\                                                                                    \<0.001
  pN                                                                                                      

  N0                                  657            36.6        81.8            Ref                      

  N1                                  723            40.2        56.3            2.797    2.288--3.419    

  N2                                  282            15.7        44.1            3.965    3.140--5.007    

  N3                                  135            7.5         30.9            5.227    3.972--6.877    

  Seventh/Eighth edition\                                                                                 \<0.001
  pT                                                                                                      

  T1a                                 271            15.1        83.9            Ref                      

  T1b                                 128            7.1         93.0            0.460    0.223--0.949    

  T2                                  106            5.9         73.5            2.305    1.485--3.577    

  T3                                  277            15.4        69.0            2.281    1.550--3.358    

  T4a                                 903            50.3        50.9            4.256    3.068--5.902    

  T4b                                 112            6.2         36.3            6.844    4.647--10.081   

  Seventh/Eighth edition\                                                                                 \<0.001
  pN                                                                                                      

  N0                                  657            36.6        81.8            Ref                      

  N1                                  381            21.2        63.5            2.289    1.811--2.894    

  N2                                  342            19.0        48.7            3.412    2.729--4.267    

  N3a                                 282            15.7        41.4            3.976    3.147--5.018    

  N3b                                 135            7.5         30.9            5.239    3.981--6.893    

  Fifth/Sixth edition\                                                                                    \<0.001
  (pTNM)                                                                                                  

  IA                                  276            15.4        91.2            Ref                      

  IB                                  203            11.3        83.2            2.018    1.215--3.352    

  II                                  461            25.7        70.2            3.857    2.524--5.893    

  IIIA                                502            27.9        49.5            7.812    5.182--11.775   

  IIIB                                157            8.7         36.4            10.608   6.828--16.482   

  IV                                  198            11.0        33.1            11.920   7.760--18.310   

  Seventh edition\                                                                                        \<0.001
  (pTNM)                                                                                                  

  IA                                  276            15.4        91.2            Ref                      

  IB                                  107            6.0         85.9            1.975    1.105--3.531    

  IIA                                 130            7.2         76.5            2.906    1.716--4.922    

  IIB                                 373            20.8        71.5            3.629    2.354--5.593    

  IIIA                                268            14.9        55.2            6.567    4.271--10.096   

  IIIB                                332            18.5        47.5            8.282    5.448--12.589   

  IIIC                                311            17.3        32.4            12.079   7.967--18.314   

  Eighth edition\                                                                                         \<0.001
  (pTNM)                                                                                                  

  IA                                  276            15.4        91.2            Ref                      

  IB                                  107            6.0         85.9            1.977    1.106--3.534    

  IIA                                 130            7.2         76.5            2.906    1.716--4.923    

  IIB                                 368            20.5        71.7            3.607    2.339--5.563    

  IIIA                                500            27.8        49.4            7.761    5.149--11.700   

  IIIB                                249            13.9        44.2            8.992    5.868--13.779   

  IIIC                                167            9.3         31.3            12.637   8.172--19.543   
  -------------------------------------------------------------------------------------------------------------------

GC, gastric cancer; HR, hazard ratio; CI, confidence interval; OS, overall survival; T, tumor; Ref, reference; pT, pathological depth of tumor invasion; pN, pathological nodal metastasis; pTNM, pathological tumor‐node‐metastasis classification of the respective gastric cancer editions.

John Wiley & Sons, Ltd

![Distribution of the survival curves according to the American Joint Committee on Cancer (AJCC) TNM classification of the (A) fifth/sixth, (B) seventh, and (C) eighth edition.](CAM4-6-2804-g001){#cam41230-fig-0001}

Also, the range of 5‐year survival for the eighth edition (91.2--31.3%) were found to be progressively wider from that of the fifth/sixth (91.2--33.1%) and seventh edition (91.2--32.4%), indicating that it possesses a larger area for stratification of gastric cancer patients. As illustrated in Figures [2](#cam41230-fig-0002){ref-type="fig"} and [3](#cam41230-fig-0003){ref-type="fig"}, this improvement was especially noted between the middle and locally advanced stages of the eighth edition against the fifth/sixth and seventh edition, respectively. Additionally, the apparent differences in survival observed from stage IIB to IIIC between the seventh and eighth edition can be primarily attributable to the different survival rates expressed by patients having pN3a and pN3b nodal disease as compared to when they were merged together as pN3ab in the seventh edition (Fig. [4](#cam41230-fig-0004){ref-type="fig"}).

![A juxtaposed comparison of the fifth/sixth edition against the eighth edition showing the differences in overall survival. The gap between the survival curves of the eighth edition are better distributed, showing higher discriminatory ability, particularly from stage IIB to IIIC.](CAM4-6-2804-g002){#cam41230-fig-0002}

![A juxtaposed comparison of the seventh against the eighth edition showing the differences in overall survival. The survival curves in the eighth edition demonstrate a greater discriminatory ability for differentiating between patients with higher stage disease, particularly for stage IIIA to IIIC.](CAM4-6-2804-g003){#cam41230-fig-0003}

![A side‐by‐side comparison illustrating the survival difference existing between patients in nodal group pN3a and pN3b compared to when classified as pN3ab.](CAM4-6-2804-g004){#cam41230-fig-0004}

However, although the distance between the survival curves of stage IIA and IIB in the eighth and seventh editions were relatively small, no intersection was observed, and they also expressed comparatively different 5‐year OS rates, 76.5% versus 71.7% and 76.5% versus 71.5%, respectively. A highly detailed illustration of the different combinations of pT/pN (Table [2](#cam41230-tbl-0002){ref-type="table-wrap"}) showed great monotonicity (continuous decrease in survival with increasing stage) and distinctiveness (difference in survival between the monotonic stages) from the old to the new edition, even though there was increased complexity of staging with each updated version. Of note, this trend could not be observed for patients with pT2 disease in the seventh and eighth editions due to their relatively low number of cases.

###### 

The number and percentage of patients with their corresponding 5‐year overall survival rates for the pT/pN combinations of the fifth/sixth, seventh and eighth AJCC TNM gastric cancer editions respectively

![](CAM4-6-2804-g005){#nlm-graphic-11}
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Furthermore, three different multivariate analyses were performed for each of the different AJCC GC editions and the clinical parameters found to be independently associated with survival (favorable characteristics in parentheses; Table [3](#cam41230-tbl-0003){ref-type="table-wrap"}) were age (≤64; *P *\<* *0.001), tumor location (lower third; *P *\<* *0.001), tumor size (\<4.5 cm; *P *=* *0.002), and total number of retrieved LN (≥16; *P *\<* *0.001).

###### 

Multivariate analyses of factors associated with 5‐year overall survival for the fifth/sixth, seventh, and eighth edition

  Characteristics                  Multivariate analysis 1[a](#cam41230-note-0005){ref-type="fn"}   Multivariate analysis 2[b](#cam41230-note-0006){ref-type="fn"}   Multivariate analysis 3[c](#cam41230-note-0007){ref-type="fn"}                                                               
  -------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- -------- --------------- --------- -------- --------------- ---------
  Age (years)                                                                                                                                                                                                                                                                                     
  ≤64                              Ref                                                                                                                                                                                                Ref                                Ref                      
  \>64                             1.439                                                            1.227--1.688                                                     \<0.001                                                          1.447    1.234--1.697    \<0.001   1.421    1.212--1.665    \<0.001
  Tumor location                                                                                                                                                                                                                                               \<0.001                            \<0.001
  \>1/3 of stomach                 Ref                                                                                                                               \<0.001                                                          Ref                      \<0.001   Ref                      \<0.001
  Upper 1/3                        0.948                                                            0.730--1.232                                                     0.691                                                            0.930    0.717--1.207    0.585     0.988    0.759--1.287    0.930
  Middle 1/3                       0.636                                                            0.440--0.919                                                     0.016                                                            0.643    0.444--0.931    0.019     0.632    0.437--0.913    0.014
  Lower 1/3                        0.569                                                            0.441--0.734                                                     \<0.001                                                          0.572    0.443--0.738    \<0.001   0.579    0.448--0.747    \<0.001
  Tumor size (cm)                                                                                                                                                                                                                                                                                 
  \<4.5                            Ref                                                                                                                               0.002                                                            Ref                      0.002     Ref                      0.003
  4.5 ≤ *T *\<* *8.0               1.092                                                            0.903--1.321                                                     0.364                                                            1.067    0.882--1.290    0.507     1.089    0.900--1.317    0.380
  ≥8.0                             1.409                                                            1.143--1.738                                                     0.001                                                            1.411    1.145--1.738    0.001     1.422    1.154--1.753    0.001
  Total LN retrieved               0.497                                                            0.416--0.593                                                     \<0.001                                                          0.473    0.397--0.563    \<0.001   0.465    0.387--0.557    \<0.001
  The fifth/sixth edition (pTNM)                                                                                                                                                                                                                                                                  
  IA                               Ref                                                                                                                               \<0.001                                                          Ref                      \<0.001   Ref                      \<0.001
  IB                               1.665                                                            0.998--2.776                                                     0.051                                                            1.480    0.825--2.654    0.188     1.451    0.809--2.603    0.212
  II                               2.750                                                            1.782--4.245                                                     \<0.001                                                          2.454    1.441--4.718    \<0.001   2.413    1.417--4.109    0.001
  IIIA                             5.495                                                            3.596--8.396                                                     \<0.001                                                          2.572    1.652--4.006    \<0.001   2.488    1.596--3.877    \<0.001
  IIIB                             10.610                                                           6.691--16.823                                                    \<0.001                                                          4.546    2.922--7.073    \<0.001   5.290    3.461--8.086    \<0.001
  IV                               11.990                                                           7.604--18.907                                                    \<0.001                                                          6.547    4.245--10.097   \<0.001   9.203    5.889--14.380   \<0.001
                                                                                                                                                                                                                                      12.416   7.983--19.312   \<0.001   13.826   8.669--22.051   \<0.001

HR, hazard ration; CI, confidence interval; ref, reference; T, tumor size; LN, lymph nodes; pTNM, pathological tumor‐node‐metastasis classification.

Multivariate analysis 1: Clinicopathological factors showing significance in univariate analysis and the stages of the fifth/sixth edition, excluding the seventh and eighth edition stages.

Multivariate analysis 2: Clinicopathological factors showing significance in univariate analysis and the stages of the seventh edition, excluding the fifth/sixth and eighth edition stage.

Multivariate analysis 3: Clinicopathological factors showing significance in univariate analysis and the stages of the eighth edition, excluding the seventh and fifth/sixth edition stage.
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Prognostic performance {#cam41230-sec-0010}
----------------------

Table [4](#cam41230-tbl-0004){ref-type="table-wrap"} illustrates the prognostic performance of the competing AJCC staging editions based on the calculations of the two different statistical methods. The best prognostic performance is determined by the lowest AIC and BIC value. As shown, the seventh edition was identified as being superior over the fifth/sixth and the eighth edition, by that were ranked as second and third, respectively. Of note, considerable overlapping of their corresponding confidence intervals (CI) was also observed.

###### 

The AIC and BIC of the different AJCC gastric cancer staging editions

        Fifth/Sixth edition   Seventh edition   Eighth edition                         
  ----- --------------------- ----------------- ---------------- ------------ -------- ------------
  AIC   9326.4                8798--9890        9315.7           8805--9891   9328.1   8792--9905
  BIC   9381.0                8840--9931        9374.8           8852--9894   9387.2   8838--9947

AIC, Akaike information criterion; BIC, Bayesian information criterion; CI, confidence interval.
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Furthermore, to investigate whether the above‐mentioned prognostic ranking would change over time, the AUC values from time‐dependent ROC analyses were performed. In here, a higher AUC values indicates the better staging system. Similarly, the seventh edition was identified as retaining its superior prognostic ability from the first to the tenth postoperative years (Table [5](#cam41230-tbl-0005){ref-type="table-wrap"}). In addition, as from the fifth postoperative year, the eighth edition was found to be superior compared to the fifth/sixth edition. However, clinically, these rankings demonstrated no significant influence due to the consistent overlapping of the 95% CI values calculated by their respective AIC, BIC, and AUC.

###### 

AUC by the time‐dependent ROC analyses based on the predictive value of the multivariate analyses of the fifth/sixth, seventh, and eighth editions

  Months   Fifth/Sixth edition   Seventh edition   Eighth edition                          
  -------- --------------------- ----------------- ---------------- -------------- ------- --------------
  12       0.765                 0.730--0.800      0.767            0.728--0.802   0.763   0.730--0.794
  24       0.803                 0.776--0.826      0.803            0.779--0.827   0.796   0.770--0.817
  36       0.793                 0.769--0.813      0.797            0.767--0.821   0.790   0.764--0.813
  48       0.773                 0.743--0.795      0.780            0.756--0.806   0.772   0.744--0.796
  60       0.765                 0.736--0.793      0.774            0.751--0.801   0.768   0.740--0.790
  120      0.782                 0.754--0.805      0.790            0.762--0.822   0.786   0.756--0.808

AUC, area under curve; ROC, receiver operating characteristic; CI, confidence interval.
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Discussion {#cam41230-sec-0011}
==========

Most studies previously comparing the different GC staging editions were mainly based on simple analysis of HR values, AIC or BIC without further validating their results using other different statistical methods. In that, we felt the need for this extensive analysis by comparing their AIC and BIC values to confirm the calculated prognostic rankings since both methods have different statistical strengths [13](#cam41230-bib-0013){ref-type="ref"}.

Our results demonstrated that both statistical methods showed similar ranking, for which the seventh edition was identified as having the best predictive ability in both short‐ and long‐term despite the small numerical differences in allocating the ranks between the competing editions. In addition, the author hypothesized that since every classification constitutes of multiple subgroups, each of them might have their own predictive power. Therefore, a range of values (e.g., confidence intervals) would be more clinically reliable than an overall value (e.g., AIC, BIC) in the sense that the former would show the predictive range of each subgroups while the latter would simply depict an overall power for the whole group. Thereby, solely relying upon the raw values of AIC and BIC may not suffice for application in clinical practice [14](#cam41230-bib-0014){ref-type="ref"}. Consequently, their corresponding confidence intervals were calculated and considerable overlapping was found; which implied [15](#cam41230-bib-0015){ref-type="ref"} that neither clinical nor statistical significance was reached to differentiate performance superiority among them and thus, signified that they possess similar prognostic ability.

Regarding the pTNM classification, the author suggests that the pT and pN should be compared as a combination because only as such they do correlate best to their corresponding overall survival (i.e., the overall survival of patients with pT2N0 will be different from those with pT2N3b). Otherwise, they may illustrate misleading, nonuniform prognoses with increase in disease severity, for example, in Table [1](#cam41230-tbl-0001){ref-type="table-wrap"} for the seventh/eighth edition, pT classification showed a noncontinuous decrease in survival. Therefore, compared to previously published studies [16](#cam41230-bib-0016){ref-type="ref"}, [17](#cam41230-bib-0017){ref-type="ref"}, [18](#cam41230-bib-0018){ref-type="ref"}, we opted to assess the prognostic power between the stages of the different editions rather separately analyzing pT and pN. Subsequently, our results more illustratively demonstrated an improving homogeneity and distinctiveness between the successive stage groups of the different staging editions (Table [2](#cam41230-tbl-0002){ref-type="table-wrap"}).

Moreover, to achieve quality cancer care, choosing the optimal treatment for patients in different disease categories might be challenging, and these concerns have been gradually addressed by the AJCC. First, they discontinued the anatomical LN staging in the fifth edition. Second, they classified patients with distant metastasis separately as stage IV in the seventh edition. Then, they separated the pN3ab subgroup to pN3a and pN3b in the latest eighth edition main stage classifications. Progressively, these changes have resulted in providing a wider range of survival from stage IA to IIIC; as illustrated in Figures [2](#cam41230-fig-0002){ref-type="fig"} and [3](#cam41230-fig-0003){ref-type="fig"}, the survival curve of stage IIIC for the eighth edition is noticeably lower than that of stage IIIC and stage IV in the seventh and fifth/sixth edition, respectively. Therefore, the eighth edition was identified as possessing the best discriminative ability for prognostic stratification of patients with gastric cancer and this will facilitate the identification of patients with higher‐stage disease for optimal therapies or enrollment in clinical trials, as the more advanced lesions have higher likelihood of nodal involvement, distant spread, recurrence and worse prognosis [19](#cam41230-bib-0019){ref-type="ref"}. Therefore, this recently revised edition, the eighth AJCC GC staging system, is a fundamental update and can be considered clinically more reliable than its previous versions.

This study is the most comprehensive one to evaluate the differences between the AJCC gastric cancer staging editions of the past two decades. However, it was limited by the fact that patients with gastric adenocarcinoma invading the EGJ could not be included for homogeneity of surgical treatment, as most of such cases were not operated by the same group of surgeons. Additionally, despite having a significant cohort of patients with R0 resections, due to greater subdivisions of classification in the eighth edition, the number of cases with pT2 disease was limited, however, since the new staging system mainly concerned patients with higher staged disease, this limitation strength was not significant to affect the statistical results of this study.

In conclusion, our comprehensive statistical assessment demonstrated that the eighth AJCC GC edition possess similar prognostic ability as the seventh, sixth, and fifth editions, which remained consistent in the long term. In addition, this new edition was also shown to provide the best discriminative ability and can thus serve as the new benchmark to stratify gastric cancer patients with higher stage disease.
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